Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Autor: Stuart, ASV, Shaw, RH, Liu, X, Greenland, M, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Darton, T, Dinesh, T, Duncan, CJA, England, A, Faust, SN, Ferreira, DM, Finn, A, Goodman, AL, Green, CA, Hallis, B, Heath, PT, Hill, H, Horsington, BM, Lambe, T, Lazarus, R, Libri, V, Lillie, PJ, Mujadidi, YF, Payne, R, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Ramsay, M, Read, RC, Robinson, H, Screaton, GR, Singh, N, Turner, DPJ, Turner, PJ, Vichos, I, White, R, Nguyen-Van-Tam, JS, Snape, MD, Com-COV2 Study Group

Publikováno v: Lancet (London, England)
Snape, M D 2022, ' Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2) : a single-blind, randomised, phase 2, non-inferiority trial ', Lancet, vol. 399, no. 10319, pp. 36-49 . https://doi.org/10.1016/S0140-6736(21)02718-5

Background Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72507942631237263460b52b50669b5
https://doi.org/10.1016/s0140-6736(21)02718-5

Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021.

Autor: Ratcliffe, Helen, Tiley, K. S., Andrews, Nick, Amirthalingam, Gayatri, Vichos, I., Morey, E., Douglas, N. L., Marinou, S., Plested, Emma, Aley, Parvinder, Galiza, Eva P., Faust, Saul N., Hughes, S., Murray, Clare S., Roderick, Marion, Shackley, Fiona, Oddie, Sam J., Lees, Tim, Turner, D. P. J., Raman, M.

Publikováno v: Archives of Disease in Childhood; Feb2023, Vol. 108 Issue 2, p123-130, 8p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.